Reportstack has announced a new market research report on Opportunity Analyzer: Celiac Disease - Opportunity Analysis and Forecast to 2018.
The celiac disease treatment market value will expand more than tenfold from an estimated $49.6 million in 2013 to $551.1 million by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 27.24%.
The report states that the US will continue to account for almost all of the celiac disease therapeutics space, which also includes the five European countries (5EU) of France, Germany, Spain, Italy and the UK. The US share will slip slightly from 99% in 2013 to just under 98% by the end of the forecast period.
The market will be driven primarily by the potential introduction of two novel pipeline drugs, Alba/Teva’s larazotide acetate and Alvine/AbbVie’s latiglutenase, which are designed to be used as adjunctive treatments to the current standard of care, a Gluten-Free Diet (GFD).
“Larazotide acetate is forecast to launch in the US in Q1 2018, with the key competitive advantage of targeting the majority of the disease population, compared with the 4–7% of refractory patients, who are currently treated with generics including steroids and immunosuppressants.
“In Q1 2019, larazotide acetate is expected to launch in the 5EU, while latiglutenase may potentially launch in the US. These pipeline drugs are forecast to increase sales in the six major markets (6MM) from $49.6 million in 2013 to $289.9 million by the end of 2019.”
The Q1 2020 may see the launch of latiglutenase in the 5EU, thereby boosting the 6MM sales further to $343.3 million, with a steady incline up to $551.1 million by 2023.
Despite the anticipated impact of these novel drugs, there are a number of barriers to growth in the celiac disease treatment market, such as limited physician and patient awareness of the condition and a lack of confidence in pipeline drugs compared with a GFD.
“Improved physician education concerning GFDs and developments in the gluten-free food market may refine the standard of care and this, in turn, may deter physicians from prescribing adjunctive treatments.”
Complete report available @ Opportunity Analyzer: Celiac Disease - Opportunity Analysis and Forecast to 2018.